When it arrives to reviewing medications, the FDA’s occupation appears simple: Make confident a drug is harmless and powerful. It is an necessary mission that this deeply dysfunctional corporation appears to be getting trouble fulfilling. The EpiPen pricing scandal and the controversial approvals of flibanserin (Addyi) to strengthen underactive sexual drive in women and eteplirsen (Exondys 51) for treating Duchenne muscular dystrophy illustrate that the Food and drug administration appears to be getting trouble fulfilling its mandate.
When it arrives to reviewing medications, the FDA’s occupation appears simple: Make confident a drug is harmless and powerful. It is an necessary mission that this deeply dysfunctional corporation appears to be getting trouble fulfilling. The EpiPen pricing scandal and the controversial approvals of flibanserin (Addyi) to strengthen underactive sexual drive in women and eteplirsen (Exondys 51) for treating Duchenne muscular dystrophy illustrate that the Food and drug administration appears to be getting trouble fulfilling its mandate.
David Gortler is a professor of pharmacology at George Washington College and a former Food and drug administration clinical officer he is now an Food and drug administration and pharmacology pro with FormerFDA.com He was also the Food and drug administration/health treatment coverage advisor for Senator Ted Cruz’s 2016 presidential marketing campaign.